SelectQuote (SLQT) Q4 2026 Earnings Call Transcript

SelectQuote reported fiscal 2026 revenue of $1.62B (+6% YoY) and adjusted EBITDA of $109M, finishing above its $90M–$100M guidance, while operating cash flow improved by $44M YoY. Management guided fiscal 2027 revenue to $1.35B–$1.45B and adjusted EBITDA to $90M–$115M (midpoint implies ~+60bps margin expansion), alongside an operating cash flow target of $60M+ (about a doubling vs. 2026) and ~$50M free cash flow. The outlook is supported by AI/technology-enabled $30M+ annualized run-rate savings and a planned shift in Healthcare Services profitability (Kansas facility efficiency and expectation of margins roughly doubling in 2027), partially offset by Inflation Reduction Act-driven revenue headwinds and continued Medicare Advantage policy volume declines.

Analysis

The market should care less about the headline revenue reset than about the mix shift from growth-at-any-cost to cash conversion. If management can translate a higher-quality book, lower CAC, and pharmacy automation into sustained free cash flow, SLQT starts to behave more like a levered cash compounder than a busted insurtech distributor. The implied rerating path is through lower funding cost and de-risked equity, not through a clean top-line re-acceleration.

The biggest second-order winner is not just SLQT’s pharmacy arm but its balance sheet: every incremental dollar of operating cash flow reduces dependence on expensive capital and increases the odds of refinancing at materially lower spreads over the next 6-18 months. The hidden loser is smaller, less tech-enabled insurance distribution and pharmacy intermediaries that can’t absorb the same compliance, servicing, and automation costs; if SLQT’s AI workflow claims are real, the competitive gap widens faster than the market expects.

The near-term risk is that investors underwrite the cash flow bridge too aggressively. If Medicare Advantage churn lasts longer, or if commission collections/working capital normalize unfavorably, the stock can gap down on any 1Q or AEP miss even if EBITDA looks fine. Falsifiers are simple: operating cash flow must track toward the $60m+ guide, Healthcare Services margins need to inflect as promised, and any evidence that the receivables balance is not converting cleanly into cash would break the thesis.

Contrarian view: consensus is likely overfocused on the revenue decline and underfocused on capital structure optionality. That said, this is still a show-me story, and the rerating probably needs one or two clean quarters of cash conversion before the market grants a higher multiple.

Key Decisions for Investors

• Long SLQT on post-earnings weakness only, with a 1-3 month horizon; thesis is cash-flow rerating rather than revenue growth. Falsify if 1Q operating cash flow or Healthcare Services EBITDA run-rate undershoots guidance.
• Use a bull call spread in SLQT into the next AEP / 1Q print if options liquidity is sufficient; structure for upside from a rerating while capping premium burn if the market keeps punishing the revenue guide-down.
• Pair trade: long SLQT / short IHF for 3-6 months to isolate beneficiary of MA churn and cost-optimization versus the payer sector still dealing with margin normalization.
• Set a watch item on SLQT refinancing / securitization commentary over the next 2 quarters; if management can credibly lower funding cost, add to the long. If not, trim on any move that prices in rapid deleveraging.